Development of prophylactic vaccines against HIV-1
1 The Sir William Dunn School of Pathology, The University of Oxford, South Parks Road, Oxford OX1 3RE, UK
2 The Weatherall Institute of Molecular Medicine, The University of Oxford, The John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
3 Oxford NIHR Biomedical Research Centre, NDM Research Building, The University of Oxford, Old Road Campus, Oxford OX3 7FZ, UK
Retrovirology 2013, 10:72 doi:10.1186/1742-4690-10-72Published: 17 July 2013
The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.